Showing results (271-280 of 286) with videos related to

Sort By:
Pageof 29
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
The Journal of Medical Investigation : JMI|September 18, 2010
Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of JapanTakanori Kanematsu, Masaki Hanibuchi, Hideki Tomimoto, et al.
Translational Lung Cancer Research|December 13, 2024
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancerNanao Terada, Hayato Koba, Shigeki Nanjo, et al.
Nature Communications|January 18, 2019
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cellsHirokazu Taniguchi, Tadaaki Yamada, Rong Wang, et al.
Cancer Science|January 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive CancersYuya Murase, Shigeki Nanjo, Sachiko Arai, et al.
Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.
NPJ Precision Oncology|January 19, 2022
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal featuresKeiko Tanimura, Tadaaki Yamada, Koutaroh Okada, et al.
Cancer Letters|February 11, 2024
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cellsKenji Morimoto, Tadaaki Yamada, Soichi Hirai, et al.
Nature Communications|September 15, 2020
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancerRong Wang, Tadaaki Yamada, Kenji Kita, et al.
Nature Communications|August 12, 2018
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLCRajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, et al.
Pageof 29